Navigation Links
GeneNews appoints Patrick Terry as lead strategic advisor for U.S. commercialization of ColonSentry(TM)
Date:10/15/2008

TORONTO, Oct. 15 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has appointed Patrick Terry as its lead strategic advisor for the U.S. commercial launch of ColonSentry(TM), the world's fist blood-based test to determine a person's current risk for colorectal cancer. Mr. Terry is one of the co-founders of Genomic Health, a leading molecular diagnostics company.

"Having co-founded one of the most successful molecular diagnostic companies in the U.S., Mr. Terry is the ideal individual to advise GeneNews on its U.S. commercialization strategy," said Dr. Heiner Dreismann, Interim CEO and Lead Director of GeneNews. "Mr. Terry is a pioneer in the field of personalized medicine. His experience growing Genomic Health from a start up to a company with $64 million in revenues will be invaluable as we prepare for U.S. commercialization of our ColonSentry(TM) test in 2009." The Company launched its lead product, the ColonSentry test, in Canada earlier this year.

Mr. Terry is the co-founder and former Director of Consumer Advocacy & Governmental Affairs at Genomic Health. He is also co-founder and former President of the International Genetic Alliance, which focuses on empowering problem solving by networking the consumer movement, centers of excellence, and high technology with patient communities around the world. Mr. Terry has published dozens of peer-reviewed scientific papers, articles, and book chapters in the field of genetics, personalized medicine, and biomedical research. Some of his activities include leadership positions on numerous trade associations, professional societies, corporate boards, and he also sits on a number of U.S. federal advisory bodies.

About GeneNews

--------------

GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on GeneNews, visit http://www.genenews.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE GeneNews Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews Announces Second Quarter Results
2. GeneNews launches worlds first blood test for colorectal cancer screening
3. GeneNews announces management changes to support commercialization of ColonSentry(TM)
4. Genenews adds two members to its Board of Directors
5. GeneNews Announces First Quarter Results
6. GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR
7. GeneNews announces 2007 year end results
8. GeneNews selected to present late-breaking abstract at AACR Annual Meeting
9. GeneNews receives ISO 13485 accreditation
10. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
11. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... States multicenter, prospective clinical study that demonstrates the accuracy of the FebriDx® ... identifying clinically significant acute bacterial and viral respiratory tract infections by testing ...
(Date:10/11/2017)... ... October 11, 2017 , ... At its national board ... Suneel I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced ... for membership in ARCS Alumni Hall of Fame . ASTER Labs is ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... pathology, announced today it will be hosting a Webinar titled, “Pathology is going ... Pathology Associates , on digital pathology adoption best practices and how Proscia improves ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published ... frozen and fresh in vitro fertilization (IVF) transfer cycles. The multi-center ... success. , After comparing the results from the fresh and frozen transfer cohorts, ...
Breaking Biology Technology:
(Date:10/4/2017)... 4, 2017  GCE Solutions, a global clinical research organization (CRO), ... anonymization solution on October 4, 2017. Shadow is designed to assist ... with policy 0070 of the European Medicines Agency (EMA) in meeting ... ... ...
(Date:6/30/2017)... June 30, 2017 Today, American Trucking ... supplier of face and eye tracking software, became ... provider program. "Artificial intelligence and ... to monitor a driver,s attentiveness levels while on ... able to detect fatigue and prevent potential accidents, ...
(Date:5/16/2017)... N.J. , May 16, 2017  Veratad Technologies, ... provider of online age and identity verification solutions, announced ... K(NO)W Identity Conference 2017, May 15 thru May 17, ... Regan Building and International Trade Center. ... the globe and in today,s quickly evolving digital world, ...
Breaking Biology News(10 mins):